Alvine Pharmaceuticals Inc.   Report issue

For profit Phase 2
Founded: Cambridge Massachusetts United States (2006)
Status: Acquired by Immunogen (2016) → now AbbVie (2023)

Organization Overview

First Clinical Trial
2008
NCT00626184
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

latiglutenase (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Celiac Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1